Publisher
e-Century Publishing Corporation
Reference26 articles.
1. Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma;Polat;Cancer Cell Int,2022
2. Feria-Romero IA, Nettel-Rueda B, Rodríguez-Florido MA, Félix-Espinoza I, Castellanos-Pallares L, Cienfuegos-Meza J, Orozco-Suárez S, Chavez JA, Escamilla-Nuñez C, Guinto G and Márquez-González H. Utility of gene tumor expression of VEGF, FOXM1*3 and CD-133 on diagnosis and prognosis of brain gliomas. medRxiv 2020; 2020-08.
3. The 2016 World Health Organization classification of tumors of the central nervous system: a summary;Louis;Acta Neuropathol,2016
4. Zhang Q, Xu B, Chen J, Chen F and Chen Z. Clinical significance of CD133 and Nestin in astrocytic tumor: the correlation with pathological grade and survival. J Clin Lab Anal 2020; 34: e23082.
5. Ishii H, Mimura Y, Zahra MH, Katayama S, Hassan G, Afify SM and Seno M. Isolation and characterization of cancer stem cells derived from human glioblastoma. Am J Cancer Res 2021; 11: 441-457.